Vizimpro (Dacomitinib) – NSCLC | HongKong DengYue Medicine

Vizimpro Application Scope

Vizimpro is an oral, irreversible EGFR tyrosine kinase inhibitor used to treat certain types of metastatic non‑small cell lung cancer.

Characteristics

• Ingredients: Dacomitinib

• Properties:

  • Mechanism: selective, irreversible inhibitor of EGFR

  • Metabolism: CYP2D6 (major), CYP3A4 (minor), active metabolite O‑desmethyl‑dacomitinib

  • Elimination half‑life: ~70 hours; excreted mostly in feces (~79%)

• Packaging Specification: Bottles of 30 tablets with child‑resistant caps (NDC-coded for each strength)

• Storage: As per label: store at room temperature; specific details in full prescribing info

• Expiry Date: Refer to the sticker on the bottle

• Executive Standard: FDA prescription drug standards

• Approval Number: Specific NDA number may vary; approved September 2018 in the US

• Date of Revision: FDA label last revised December 2020; product approved September 2018

• Manufacturer: Pfizer Inc.

Guidelines for the Use of Vizimpro

• Dosage and Administration:

  • Starting dose: 45 mg orally once daily, with or without food, at the same daily time

  • Missed dose/vomiting: do not make up; continue next day

  • Dose reductions for toxicity: first reduction 30 mg, second 15 mg

  • Acid‑reducing medications:

    • Avoid proton pump inhibitors.

    • If using H₂‑blocker, take dacomitinib ≥ 6 hrs before or ≥ 10 hrs after

• Adverse Reactions:

  • Common (>20%): diarrhea, rash, paronychia, stomatitis, dry skin, decreased appetite, weight loss, alopecia, cough, pruritus

  • Serious:

    • interstitial lung disease/pneumonitis (0.5%, fatal 0.3%)

    • grade 3–4 diarrhea (~11%, fatal 0.3%), rash (grade 3–4 in ~21%)

• Contraindications: None explicitly listed

• Precautions:

  • Monitor for ILD/pneumonitis; permanently stop if confirmed

  • Manage diarrhea and rash promptly; use anti‑diarrheals, topical/systemic skin treatments; adjust dose as needed

  • Can cause fetal harm: require pregnancy test and effective contraception during and ≥17 days after treatment

  • Avoid breastfeeding during treatment and for ≥17 days after the last dose

Vizimpro Interactions

• Drug Interactions:

  • PPIs reduce absorption; avoid them

  • H₂‑blockers/antacids: separate dosing times

  • Inhibits CYP2D6: can increase plasma concentration of substrates significantly (e.g., dextromethorphan up 9‑fold)

  • Avoid concomitant use with drugs heavily metabolized by CYP2D6

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.